Penn Pharma Invests in Manufacturing Capacity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Penn Pharma Invests in Manufacturing Capacity


Penn Pharma has announced its plans to invest in additional tablet manufacturing and coating capacity to meet customer demand.  This investment is in addition to the £14 million ($21.2 million) recently invested in a solid dose contained manufacturing facility to handle potent active pharmaceutical ingredients.  
  
The new £3 million ($4.5 million) investment follows the recent completion of Penn Pharma’s new 15,000-ft2 site for the clinical and commercial manufacture of tablets and capsules.

Penn Pharma has been providing pharmaceutical services for more than 30 years and employs 275 staff on its two sites in South Wales, UK.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here